Who's in and who's out of Goldman Sachs' '10 products that will change the industry'?
This article was originally published in Scrip
Goldman Sachs has updated its annual list of the ten products that it believes can transform the industry, dropping six products from its 2014 list, but keeping the faith in immune-oncology as the largest opportunity for pharma.
You may also be interested in...
Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Two different outcomes for two different CD4/6 inhibitors – Eli Lilly’s Verzenio and Pfizer’s Ibrance – put the Lilly drug on track to be a new standard of care in high-risk early stage HR+, HER2-negative breast cancer. Novartis’s Kisqali could follow.